A. Chantry

发表

TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model

G. Reilly, B. Walkley, J. Down, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Analyzing mRNA expression identifies Smad3 as a microRNA-140 target regulated only at protein level.

Vincent Moulton, Tamas Dalmay, Helio Pais, 2010, RNA.

Guidelines for the use of imaging in the management of patients with myeloma

Vicky Goh, Guy Pratt, Majid Kazmi, 2017, British journal of haematology.

Frontiers in PROTACs.

A. Hemmings, A. Chantry, Gregory R Hughes, 2021, Drug discovery today.

How ubiquitination regulates the TGF‐β signalling pathway: New insights and new players

S. Soond, A. Chantry, Surinder M. Soond, 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

Reversible ubiquitination regulates the Smad/TGF-β signalling pathway

P. Dijke, A. Chantry, T. Grocott, 2006 .

The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-β signalling

P. Dijke, R. Cohen, A. Chantry, 2005, Oncogene.

NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease

J. Snowden, R. Walker, H. Evans, 2015, PloS one.

A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging.

C. Svendsen, W. Keith, I. Bellantuono, 2009, Biochimica et biophysica acta.

A Small Molecule Modulator of Prion Protein Increases Human Mesenchymal Stem Cell Lifespan, Ex Vivo Expansion, and Engraftment to Bone Marrow in NOD/SCID Mice

W. Keith, I. Bellantuono, A. Thrasher, 2012, Stem cells.

Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience

B. Sharrack, J. Snowden, P. Sarrigiannis, 2020, Journal of Neurology.

Inhibiting activin‐A signaling stimulates bone formation and prevents cancer‐induced bone destruction in vivo

M. Bouxsein, P. Croucher, T. Arnett, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors.

A. Chantry, 1995, The Journal of biological chemistry.

Smad7 Binds Differently to Individual and Tandem WW3 and WW4 Domains of WWP2 Ubiquitin Ligase Isoforms

S. Soond, James Tolchard, A. Chantry, 2019, International journal of molecular sciences.

Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods☆

R. Walker, M. Lawson, A. Chantry, 2016, Bone.

Discovery of Small Molecule WWP2 Ubiquitin Ligase Inhibitors.

S. Monaco, J. Angulo, A. Hemmings, 2018, Chemistry.

WWP2 ubiquitin ligase and its isoforms: New biological insight and promising disease targets

A. Chantry, 2011, Cell cycle.

Novel WWP2 ubiquitin ligase isoforms as potential prognostic markers and molecular targets in cancer.

S. Soond, A. Hemmings, I. Clark, 2013, Biochimica et biophysica acta.

Smad3 mediates transforming growth factor-beta-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways.

Jiahuai Han, S. Leivonen, L. Hakkinen, 2002, The Journal of biological chemistry.

Upregulation of the TGFβ signalling pathway by Bcr‐Abl: Implications for haemopoietic cell growth and chronic myeloid leukaemia

J. Melo, A. Chantry, V. Frost, 2007 .

Characterisation of TGF-beta2 signalling and function in a human lens cell line.

K. Lazaridis, S. Tamiya, A. Chantry, 2004, Experimental eye research.

Myeloma impairs mature osteoblast function but causes early expansion of osteo‐progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model

P. Croucher, K. Yong, D. Lath, 2016, British journal of haematology.

Time to redefine Myeloma

J. Snowden, E. Low, K. Ramasamy, 2015, British journal of haematology.

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo

J. Down, D. Lath, H. Evans, 2018, PloS one.

The Pathophysiology of Myeloma Bone Disease: Bone Remodelling and the Role of Osteoclasts

A. Chantry, R. Andrews, A. Ashcroft, 2021 .

Bone Pain in Multiple Myeloma (BPMM)—A Protocol for a Prospective, Longitudinal, Observational Study

T. L. Andersen, A. Chantry, A. Heegaard, 2021, Cancers.

The Conserved Glutamine-rich Region of Chick Csal1 and Csal3 Mediates Protein Interactions with Other Spalt Family Members

A. Münsterberg, A. Chantry, E. Farrell, 2003, The Journal of Biological Chemistry.

EZH2 inhibition enhances TRAIL responses in multiple myeloma but not in quiescent cells

S. Haywood-Small, N. Cross, A. Chantry, 2021, bioRxiv.

Cross-reactivity of amylin with calcitonin-gene-related peptide binding sites in rat liver and skeletal muscle membranes.

B. Leighton, A. Chantry, A. Day, 1991, The Biochemical journal.

Zinc Ions Stabilise the Association of Basic Protein with Brain Myelin Membranes

P. Glynn, A. Chantry, Charles Earl, 1988, Journal of neurochemistry.

The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1‐Fluoro‐2‐(Imidazo‐[1,2‐α]Pyridin‐3‐yl)‐Ethyl‐Bisphosphonate)

A. Mazur, M. Tsoumpra, J. Dunford, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A novel metalloproteinase associated with brain myelin membranes. Isolation and characterization.

P. Glynn, N. Gregson, A. Chantry, 1989, The Journal of biological chemistry.

A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.

J. Paton-Hough, M. Lawson, A. Chantry, 2015, Bone.

Assessment of droplet digital polymerase chain reaction for measuring BCR‐ABL1 in chronic myeloid leukaemia in an international interlaboratory study

L. Beppu, E. Ma, W. Tang, 2021, British journal of haematology.

ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation

Li Lei, Li Lei, Rong Fan, 2020, Stem Cell Research & Therapy.

Metalloendoprotease Cleavage of 18.2‐ and 14.1‐Kilodalton Basic Proteins Dissociating from Rodent Myelin Membranes Generates 10.0‐ and 5.9‐Kilodalton G‐Terminal Fragments

P. Glynn, N. Groome, A. Chantry, 1988, Journal of neurochemistry.

Basic Protein Dissociating from Myelin Membranes at Physiological Ionic Strength and pH Is Cleaved into Three Major Fragments

P. Glynn, M. Cuzner, A. Chantry, 1987, Journal of neurochemistry.

Low-dose methotrexate in myeloproliferative neoplasm models

J. Snowden, J. Sayers, M. Zeidler, 2017, Haematologica.

A novel metalloproteinase originally isolated from brain myelin membranes is present in many tissues.

P. Glynn, A. Chantry, 1990, The Biochemical journal.

A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells

Hideo Tanaka, A. Chantry, Paul G Smith, 2012, Oncotarget.

Reversible ubiquitination regulates the Smad/TGF-beta signalling pathway.

P. ten Dijke, A. Chantry, T. Grocott, 2006, Biochemical Society transactions.

The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma

D. Chauhan, J. Morgan, Roisin M. McAvera, 2020, Oncogene.

Degradation of myelin basic protein by a membrane-associated metalloprotease: Neural distribution of the enzyme

P. Glynn, N. Gregson, A. Chantry, 1992, Neurochemical Research.

A new epitope on human myelin basic protein arising from cleavage by a metalloendoprotease associated with brain myelin membranes

P. Glynn, J. Newcombe, J. Findlay, 1988, Journal of Neuroimmunology.

Two-dimensional electrophoretic characterization of microheterogeneous myelin basic protein fragments.

P. Glynn, A. Chantry, 1986, Analytical biochemistry.

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs

C. Cooper, M. Drayson, K. Ramasamy, 2019, Journal of bone oncology.

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

M. Chapman, M. Drayson, S. Quezada, 2022, BMJ Open.

Self-regulated Pax gene expression and modulation by the TGFbeta superfamily.

M. Eccles, A. Chantry, T. Grocott, 2008, Critical reviews in biochemistry and molecular biology.

Emotions and beliefs arising from replacement blood donation may hinder transitioning to exclusive voluntary non‐remunerated blood donation

Z. Danielle, Kimberly Gomez, A. Chantry, 2020, ISBT Science Series.

Blood donors' attitudes towards voluntary non‐remunerated donation in Trinidad and Tobago

G. Legall, A. Chantry, S. Pooransingh, 2017, Transfusion medicine.

A university - Led initiative to promote voluntary non-remunerated blood donation in a developing country.

A. Chantry, K. Charles, Deepak Lall, 2019, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Blood utilisation in a developing society: what is the best index of efficiency?

A. Chantry, D. Murray, K. Charles, 2018, Transfusion medicine.

A follow‐up survey of knowledge, attitudes and practices surrounding blood donation in Trinidad and Tobago

G. Legall, A. Chantry, S. Pooransingh, 2017 .

Ca2+/Calmodulin-dependent Kinase II Phosphorylates the Epidermal Growth Factor Receptor on Multiple Sites in the Cytoplasmic Tail and Serine 744 within the Kinase Domain to Regulate Signal Generation*

A. Chantry, R L Feinmesser, S J Wicks, 1999, The Journal of Biological Chemistry.

Mesenchymal lineage cells and their importance in B lymphocyte niches.

L. Purton, A. Green, A. Chantry, 2017, Bone.

Inactivation of Smad-Transforming Growth Factor β Signaling by Ca2+-Calmodulin-Dependent Protein Kinase II

R. Mason, N. Abdel-Wahab, A. Chantry, 2000, Molecular and Cellular Biology.

Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma.

A. Chantry, C. Buckle, P. Talley, 2015, British medical bulletin.

The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma

M. Lawson, A. Chantry, G. Stewart, 2021, Cancers.

Broccoli Consumption Interacts with GSTM1 to Perturb Oncogenic Signalling Pathways in the Prostate

Alexandra M. E. Jones, R. Ball, D. Barrett, 2008, PloS one.

A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.

W. J. Irwin, J. Coulson, D. Poyner, 1996, Molecular pharmacology.

The MH1 domain of Smad3 interacts with Pax6 and represses autoregulation of the Pax6 P1 promoter

Terje Johansen, Timothy Grocott, G. Wheeler, 2007, Nucleic acids research.

Self-Regulated Pax Gene Expression and Modulation by the TGFβ Superfamily

M. Eccles, A. Chantry, T. Grocott, 2008 .

Decorin suppresses transforming growth factor-beta-induced expression of plasminogen activator inhibitor-1 in human mesangial cells through a mechanism that involves Ca2+-dependent phosphorylation of Smad2 at serine-240.

R. Mason, N. Abdel-Wahab, A. Chantry, 2002, The Biochemical journal.

The Comparative Role of Activator Protein 1 and Smad Factors in the Regulation of Timp-1 and MMP-1 Gene Expression by Transforming Growth Factor-β1*

D. Edwards, I. Clark, A. Rowan, 2003, The Journal of Biological Chemistry.

HER-2/c-erbB2 is phosphorylated by calmodulin-dependent protein kinase II on a single site in the cytoplasmic tail at threonine-1172.

A. Means, A. Chantry, K. Gray, 1996, Oncogene.

Spontaneous splenic rupture: an unusual presentation of CML

N. Atkey, L. Wyld, A. Chantry, 2011, BMJ Case Reports.

Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFβ signalling and EMT

S. Soond, A. Chantry, 2011, Oncogene.

Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo

P. Croucher, S. Vitovski, M. Lawson, 2012, PloS one.

New agents in the Treatment of Myeloma Bone Disease

J. Snowden, M. Lawson, A. Chantry, 2017, Calcified Tissue International.

TGF-β-Elicited Induction of Tissue Inhibitor of Metalloproteinases (TIMP)-3 Expression in Fibroblasts Involves Complex Interplay between Smad3, p38α, and ERK1/2

S. Leivonen, V. Kähäri, D. Edwards, 2013, PloS one.

Early phase TGFβ receptor signalling dynamics stabilised by the deubiquitinase UCH37 promotes cell migratory responses.

S. Soond, Steve Powell, A. Chantry, 2011, The international journal of biochemistry & cell biology.

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models

J. Snowden, J. Down, S. Tazzyman, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Mechanisms and treatment of bone pain in multiple myeloma.

M. Davies, A. Chantry, Samuel Fingas, 2019, Current opinion in supportive and palliative care.

Myeloma Bone Disease: The Osteoblast in the Spotlight

Janet E Brown, M. Lawson, A. Chantry, 2021, Journal of clinical medicine.

Adjacent carboxyterminal tyrosine phosphorylation events identify functionally distinct ErbB2 receptor subsets: implications for molecular diagnostics.

R. Epstein, G. Huang, A. Chantry, 1998, Experimental cell research.

Inhibiting Dickkopf‐1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

J. Shaughnessy, D. Heath, J. Snowden, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter‐laboratory study: Is it ready for primetime use?

P. Wallace, J. Snowden, D. Barnett, 2019, Cytometry. Part B, Clinical cytometry.

HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models

S. Tazzyman, D. Lath, M. Muthana, 2023, Viruses.

SMAD proteins directly suppress PAX2 transcription downstream of transforming growth factor-beta 1 (TGF-β1) signalling in renal cell carcinoma

M. Eccles, C. Stayner, G. Kaur, 2018, Oncotarget.

What Can Patient Narratives Reveal to Us About the Experience of a Diagnosis of Myeloma? A Qualitative Scoping Review

A. Chantry, B. Gibson, Zoë Rubins, 2022, Journal of patient experience.

Myeloma bone disease: pathogenesis, current treatments and future targets.

J. Snowden, R. Walker, M. Lawson, 2014, British medical bulletin.

Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

M. Dimopoulos, D. Heath, P. Croucher, 2006, British journal of haematology.

Multiple myeloma-A painful disease of the bone marrow.

M. Lawson, A. Chantry, A. Heegaard, 2020, Seminars in cell & developmental biology.

Overexpression of ErbB2 impairs ligand‐dependent downregulation of epidermal growth factor receptors via a post‐transcriptional mechanism

R. Epstein, A. Chantry, Guo Huang, 1999, Journal of cellular biochemistry.

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma

D. Hose, K. Breckpot, M. Törngren, 2023, Journal for ImmunoTherapy of Cancer.

Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor

M. Oksvold, H. Huitfeldt, W. Langdon, 2003, Oncogene.

Bone Research Society, Annual Meeting 2017 Proceedings

P. Tsai, T. Spector, J. Bell, 2018, Journal of musculoskeletal & neuronal interactions.

Comparison of the CELLEX™ and UVAR‐XTS™ closed‐system extracorporeal photopheresis devices in the treatment of chronic graft‐versus‐host disease

P. Taylor, A. Alfred, A. Chantry, 2017, Journal of clinical apheresis.

Metastatic infiltration of nervous tissue and periosteal nerve sprouting in multiple myeloma induced bone pain

L. Jensen, P. Dougherty, D. Neves, 2023, bioRxiv.

Metastatic infiltration of nervous tissue and periosteal nerve sprouting in multiple 1 myeloma induced bone pain

L. Jensen, P. Dougherty, D. Neves, 2022 .

Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.

M. Dimopoulos, D. Heath, P. Croucher, 2006 .

SAHA‐induced TRAIL‐sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture

A. Chantry, N. Cross, A. Arhoma, 2017, Experimental cell research.

Apomine™, an inhibitor of HMG‐CoA‐reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo

P. Croucher, R. Russell, K. Vanderkerken, 2007, International journal of cancer.

Metastatic infiltration of nervous tissue and periosteal nerve sprouting in multiple myeloma induced bone pain

L. Jensen, P. Dougherty, D. Neves, 2023, bioRxiv.

Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.

C. Craddock, J. Snowden, K. Peggs, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study

N. Potter, D. Travis, C. Thiede, 2023, Blood advances.

P3. A soluble activin type II receptor prevents the development of myeloma bone disease

D. Heath, P. Croucher, J. Seehra, 2008 .

The Comparative Role of Activator Protein 1 and Smad Factors in the Regulation of Timp-1 and MMP-1 Gene Expression by Transforming Growth Factor- (cid:1) 1*

D. Edwards, I. Clark, A. Rowan, 2003 .